SCHEMBL601153

SCHEMBL601153

CC(=O)[C@H]1C(C)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.67
SHBG P04278 8/20 0.67
SMN1; SMN2 Q16637 7/20 0.67
SERPINA6 P08185 7/20 0.67
CYP3A4 P08684 6/20 0.67
MAPK1 P28482 6/20 0.67
ALDH1A1 P00352 6/20 0.67
TSHR P16473 5/20 0.67
MAPT P10636 5/20 0.67
NR3C1 P04150 4/20 0.67
PGR P06401 3/20 0.67
AR P10275 3/20 0.67
GPBAR1 Q8TDU6 3/20 0.67
SIGMAR1 Q99720 3/20 0.67
PMP22 Q01453 3/20 0.67
NPSR1 Q6W5P4 3/20 0.67
CYP2C9 P11712 2/20 0.67
HIF1A Q16665 2/20 0.67
CYP2C19 P33261 2/20 0.67
MEN1 O00255 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL601152 1.00 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL5572178 1.00 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11766174 0.89 SHBG (0.64) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11766184 0.89 SHBG (0.64) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL572119 0.89 SHBG (0.77) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11544123 0.89 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL638332 0.89 SHBG (0.77) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL11544128 0.89 LMNA (0.67) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL9242740 0.88 SHBG (0.63) LMNASHBGSMN1; SMN2SERPINA6CYP3A4
SCHEMBL8781737 0.88 LMNA (0.69) LMNASHBGSMN1; SMN2SERPINA6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6844333-B1 Method of treating atherosclerosis THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2005-01-18 US claimed
US-4902681-A Inhibition of immune clearance using progesterone analogues UNIVERSITY OF PENNSYLVANIA (US) 1990-02-20 US claimed
US-20150353596-A1 17-Substituted Steroid Compounds HOLLIS-EDEN PHARMACEUTICALS, INC. 2015-12-10 US disclosed
EP-1807118-B1 STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS HARBOR BIOSCIENCES INC (US) 2014-03-12 EP disclosed
US-8541600-B2 11-aza, 11-thia and 11-oxa sterol compounds and compositions Harbor Therapeutics, Inc. (US) 2013-09-24 US disclosed
EP-2471536-A1 STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS Harbor BioSciences, Inc. (US) 2012-07-04 EP disclosed
US-20120101052-A9 15-THIA STEROID COMPOUNDS AND COMPOSITIONS BIOVIE INC. 2012-04-26 US disclosed
US-20120041016-A1 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions BIOVIE INC. 2012-02-16 US disclosed
US-8022234-B2 Compounds and compositions HARBOR BIOSCIENCES, INC. (US) 2011-09-20 US disclosed
US-20110218162-A1 15-THIA STEROID COMPOUNDS AND COMPOSITIONS FRINCKE JAMES M 2011-09-08 US disclosed
US-7947846-B2 15-OXA-steroid compounds HARBOR BIOSCIENCES, INC. (US) 2011-05-24 US disclosed
US-4908358-A Inhibition of immune clearance using progesterone analogues TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 1990-03-13 US disclosed
US-4902681-A Inhibition of immune clearance using progesterone analogues UNIVERSITY OF PENNSYLVANIA (US) 1990-02-20 US disclosed
US-4902681-A Inhibition of immune clearance using progesterone analogues UNIVERSITY OF PENNSYLVANIA (US) 1990-02-20 US disclosed
US-4891426-A EPOXIDATION WITH PERACID THE UPJOHN COMPANY (US) 1990-01-02 US disclosed
EP-0308412-A1 16-g(a)-METHYLATION PROCESS. UPJOHN CO (US) 1989-03-29 EP disclosed
WO-1987007612-A1 16alpha-METHYLATION PROCESS THE UPJOHN COMPANY (US) 1987-12-17 WO disclosed
US-4704455-A 16α-methylatedΔ17(20)-corticoids THE UPJOHN COMPANY (US) 1987-11-03 US disclosed
EP-0238545-A1 C 20? THROUGH C 26? AMINO STEROIDS. UPJOHN CO (US) 1987-09-30 EP disclosed
WO-1987001706-A2 C20 THROUGH C26 AMINO STEROIDS THE UPJOHN COMPANY (US) 1987-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353596-A1 17-Substituted Steroid Compounds HSD3B1, HSD3B2, HSD17B13 LMNA 3127/4885SHBG 55/4885SMN1; SMN2 3201/4885
US-20120101052-A9 15-THIA STEROID COMPOUNDS AND COMPOSITIONS MPL, THPO, ALOX15 LMNA 3783/4885SHBG 73/4885SMN1; SMN2 3274/4885
US-20120041016-A1 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions CYP51A1, HSD11B1, HSD3B1 LMNA 4455/4885SHBG 105/4885SMN1; SMN2 4528/4885
US-20110218162-A1 15-THIA STEROID COMPOUNDS AND COMPOSITIONS MPL, THPO, ALOX15 LMNA 3783/4885SHBG 73/4885SMN1; SMN2 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.